- Home
- TPH vs RARE Comparison
TPH vs RARE Comparison
Compare TPH & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPH
- RARE
- Stock Information
- Founded
- TPH 2009
- RARE 2010
- Country
- TPH United States
- RARE United States
- Employees
- TPH N/A
- RARE N/A
- Industry
- TPH Homebuilding
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- TPH Consumer Discretionary
- RARE Health Care
- Exchange
- TPH Nasdaq
- RARE Nasdaq
- Market Cap
- TPH 2.9B
- RARE 2.6B
- IPO Year
- TPH N/A
- RARE 2014
- Fundamental
- Price
- TPH N/A
- RARE $30.86
- Analyst Decision
- TPH Buy
- RARE Strong Buy
- Analyst Count
- TPH 6
- RARE 14
- Target Price
- TPH $41.20
- RARE $86.64
- AVG Volume (30 Days)
- TPH 977.9K
- RARE 1.7M
- Earning Date
- TPH 10-23-2025
- RARE 11-04-2025
- Dividend Yield
- TPH N/A
- RARE N/A
- EPS Growth
- TPH N/A
- RARE N/A
- EPS
- TPH 3.96
- RARE N/A
- Revenue
- TPH $4,041,885,000.00
- RARE $610,159,000.00
- Revenue This Year
- TPH N/A
- RARE $19.72
- Revenue Next Year
- TPH $1.33
- RARE $23.29
- P/E Ratio
- TPH $8.17
- RARE N/A
- Revenue Growth
- TPH N/A
- RARE 26.77
- 52 Week Low
- TPH $27.90
- RARE $25.81
- 52 Week High
- TPH $46.91
- RARE $58.00
- Technical
- Relative Strength Index (RSI)
- TPH 35.46
- RARE 49.00
- Support Level
- TPH $33.65
- RARE $29.57
- Resistance Level
- TPH $34.96
- RARE $31.70
- Average True Range (ATR)
- TPH 0.79
- RARE 1.19
- MACD
- TPH -0.20
- RARE 0.10
- Stochastic Oscillator
- TPH 3.53
- RARE 51.14
About TPH Tri Pointe Homes Inc.
Tri Pointe Homes Inc is an American construction company that focuses on residential construction. The company is engaged in the design, construction, and sale of single-family attached and detached homes in different states across the United States. Its operations are organized into two principal businesses: homebuilding. which generates key revenue, and financial services. The homebuilding business has three reportable operating segments, based on the geographical layout of the markets, and includes West region, Central region, and East region. The company's financial services operation is comprised of its Tri Pointe Connect mortgage financing operations, Tri Pointe Assurance title and escrow services operations, and Tri Pointe Advantage property and casualty insurance agency operations.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.